|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||43.20 - 43.20|
|52-week range||28.10 - 49.86|
|Beta (5Y monthly)||0.98|
|PE ratio (TTM)||20.28|
|Forward dividend & yield||1.21 (2.81%)|
|Ex-dividend date||17 May 2023|
|1y target est||N/A|
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Investors need to pay close attention to Fresenius Medical Care (FMS) stock based on the movements in the options market lately.
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.